糖尿病合并左主干病变:EXCEL试验中PCI与CABG的疗效比较
EXCEL试验预设亚组分析纳入1905例左主干病变且SYNTAX评分≤32的患者,随机接受依维莫司洗脱支架PCI或CABG。糖尿病与非糖尿病患者中PCI与CABG的3年复合终点(死亡、心梗或卒中)均相似,但糖尿病患者3年复合终点显著高于非糖尿病患者。
要点
- 糖尿病患者3年复合终点发生率显著高于非糖尿病患者(20.0% vs 12.9%)。
- 糖尿病与非糖尿病患者中,PCI与CABG的3年复合终点均无显著差异。
- 3年全因死亡PCI组13.6% vs CABG组9.0%,但糖尿病状态与治疗无显著交互作用。
核心结论
- 在左主干病变且SYNTAX评分≤32的患者中,糖尿病与非糖尿病患者接受PCI或CABG的30天和3年相对结局一致。
研究设计与样本
- EXCEL随机试验预设亚组分析,纳入1905例左主干病变且SYNTAX评分≤32的患者,1:1随机接受依维莫司洗脱支架PCI或CABG,按糖尿病分层。
- 糖尿病组554例,非糖尿病组1350例。
主要发现
- 糖尿病组3年复合终点(全因死亡、卒中或心梗)显著高于非糖尿病组(20.0% vs 12.9%,p<0.001)。
- 糖尿病组PCI与CABG的3年复合终点相似(20.7% vs 19.3%,HR 1.03,95%CI 0.71-1.50,p=0.87)。
- 非糖尿病组PCI与CABG的3年复合终点相似(12.9% vs 12.9%,HR 0.98,95%CI 0.73-1.32,p=0.89)。
- 3年全因死亡PCI组13.6%,CABG组9.0%(p=0.046),但糖尿病状态与治疗无显著交互作用(p=0.22)。
- 糖尿病状态与治疗对3年复合终点(交互p=0.82)、30天死亡/心梗/卒中(交互p=0.61)及3年死亡/心梗/卒中/缺血驱动血运重建(交互p=0.65)均无显著交互作用。
临床怎么用
- 对于左主干病变且SYNTAX评分≤32的糖尿病患者,PCI与CABG的3年复合终点相似,治疗决策需结合个体情况。
- 糖尿病患者3年复合终点风险显著高于非糖尿病患者,应加强危险因素管理。
局限性
- 为预设亚组分析,糖尿病亚组样本量有限(n=554)。
- SYNTAX评分为站点评估,非核心实验室评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomized EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial reported a similar rate of the 3-year composite primary endpoint of death, myocardial infarction (MI), or stroke in patients with left main coronary artery disease (LMCAD) and site-assessed low or intermediate SYNTAX scores treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Whether these results are consistent in high-risk patients with diabetes, who have fared relatively better with CABG in most prior trials, is unknown. OBJECTIVES: In this pre-specified subgroup analysis from the EXCEL trial, the authors sought to examine the effect of diabetes in patients with LMCAD treated with PCI versus CABG. METHODS: Patients (N = 1,905) with LMCAD and site-assessed low or intermediate CAD complexity (SYNTAX scores ≤32) were randomized 1:1 to PCI with everolimus-eluting stents versus CABG, stratified by the presence of diabetes. The primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 years. Outcomes were examined in patients with (n = 554) and without (n = 1,350) diabetes. RESULTS: The 3-year composite primary endpoint was significantly higher in diabetic compared with nondiabetic patients (20.0% vs. 12.9%; p < 0.001). The rate of the 3-year primary endpoint was similar after treatment with PCI and CABG in diabetic patients (20.7% vs. 19.3%, respectively; hazard ratio: 1.03; 95% confidence interval: 0.71 to 1.50; p = 0.87) and nondiabetic patients (12.9% vs. 12.9%, respectively; hazard ratio: 0.98; 95% confidence interval: 0.73 to 1.32; p = 0.89). All-cause death at 3 years occurred in 13.6% of PCI and 9.0% of CABG patients (p = 0.046), although no significant interaction was present between diabetes status and treatment for all-cause death (p = 0.22) or other endpoints, including the 3-year primary endpoint (p = 0.82) or the major secondary endpoints of death, MI, or stroke at 30 days (p = 0.61) or death, MI, stroke, or ischemia-driven revascularization at 3 years (p = 0.65). CONCLUSIONS: In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with everolimus-eluting stents versus CABG were consistent in diabetic and nondiabetic patients with LMCAD and site-assessed low or intermediate SYNTAX scores.(Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).
引用
- Milojevic M, Serruys PW, Sabik JF, et al. Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. J Am Coll Cardiol. 2019. PMID: 30947913. doi:10.1016/j.jacc.2019.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。